CellaVision AB

Good profitability despite negative COVID-19-effect - Seite 5

Zlatko Rihter, VD, CellaVision AB, Tel: [phone],
E-mail: [e-mail]

Magnus Blixt, CFO, CellaVision AB, Tel: [phone]
E-mail: [e-mail]

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells products for sample preparation and systems for routine analysis of blood and other body fluids in health care services. The analyzes form an important basis for rapid and correct disease diagnoses, for example in the case of infections and serious cancers. CellaVision's products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 18 local market support organizations covering more than 40 countries. In 2019, sales were SEK 462 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Publication
This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 8:20 a.m. CET on July 16, 2020.

Attachment

• CellaVision Interim report January-June 2020